作者: Norman Oneil
DOI: 10.5772/21979
关键词:
摘要: The role of liver biopsy (LB), the traditional gold standard for assessing disease, continues to evolve1-4. Fewer biopsies are being done diagnosis as noninvasive tests such new imaging techniques and accurate serological can now be instead in many cases2-4. Most currently performed parenchymal disease not make specific but assess damage (the degree inflammation, fibrosis) or response therapy5. In contrast past when nearly all were diagnostic purpose, presently more than 50% staging versus 15% diagnosing disease5. addition, often help guiding management hepatitis C nonalcoholic steatohepatitis therapy2, 3. increased use transplantation treatment end stage diverse etiologies has led differentiate cause graft dysfunction suitability potential donors transplantation1-3. dramatic increase obesity, diabetes, hyperlipidaemia hypertension metabolic syndrome) western societies its accompanying fatty problems requiring histological assessment2. Evaluation histology remains very important LB is reported change clinical 8-14%, 12-18% frequency test monitoring 36% cases5. Hence main indication a) chronic hepatitisfor grading, staging, establishing a therapeutic strategy therapy, b)unexplained abnormal function hepatomegaly c) follow up patients after transplantation. However no free risk it an invasive procedure. Rational assessment overall however hampered by wide variation outcome existing literature.